<DOC>
	<DOC>NCT02501928</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and tolerability of fesoterodine following once daily long-term treatment in Japanese pediatric neurogenic detrusor overactivity (NDO) subjects.</brief_summary>
	<brief_title>Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.</brief_title>
	<detailed_description>This is a Phase 3, multi-center, open-label long-term extension study in Japanese NDO subjects who participated and completed in the precedent Study A0221047 which is a 24 weeks, randomized, open label study, to investigate the safety and tolerability of fesoterodine. This study consists of a 28-week open-label treatment period followed by a 4-week follow-up. In addition, subjects in the oxybutynin arm of the precedent Study A0221047 will continue the fesoterodine treatment until Week 40 visit in this study, in order to obtain fesoterodine 1 year treatment data.</detailed_description>
	<mesh_term>Urinary Bladder, Neurogenic</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>â€¢Subjects who completed 24 week treatment and all visit procedures in the precedent Study A0221047 Subjects who had major protocol violation (as determined by the Sponsor) in Study A0221047 Concomitant medications which may increase the risk to subjects or confound study results Other medical conditions which may increase the risk to subjects or confound study results</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>neurogenic detrusor overactivity</keyword>
	<keyword>fesoterodine</keyword>
	<keyword>Japan</keyword>
</DOC>